Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
Abstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK‐positive NSCLC. This study aimed to analyze the real‐world efficacy and outcome when administered crizot...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15213 |
| _version_ | 1797299742710956032 |
|---|---|
| author | Da Som Jeon Cheol‐kyu Park Seung Joon Kim Chan Kwon Park Yoon Soo Chang Chi Young Jung Sung Yong Lee Shin‐Yup Lee Jeong‐Seon Ryu Jeong Eun Lee Kye Young Lee Tae Won Jang Seung Hun Jang Seong Hoon Yoon Sang Hoon Lee Chang‐min Choi Hyeong Ryul Kim Yeon Joo Kim |
| author_facet | Da Som Jeon Cheol‐kyu Park Seung Joon Kim Chan Kwon Park Yoon Soo Chang Chi Young Jung Sung Yong Lee Shin‐Yup Lee Jeong‐Seon Ryu Jeong Eun Lee Kye Young Lee Tae Won Jang Seung Hun Jang Seong Hoon Yoon Sang Hoon Lee Chang‐min Choi Hyeong Ryul Kim Yeon Joo Kim |
| author_sort | Da Som Jeon |
| collection | DOAJ |
| description | Abstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK‐positive NSCLC. This study aimed to analyze the real‐world efficacy and outcome when administered crizotinib, the first approved target agent for ALK‐positive NSCLC, according to first‐ or late‐line treatment. Methods A total of 290 patients with ALK‐positive advanced NSCLC who were treated with crizotinib in 15 institutions in South Korea from January 2009 to December 2018 were enrolled. Results The median age of patients was 57.0 years, and 50.3% were male. The median follow‐up duration was 29.3 months. Among them, 113 patients received crizotinib as first‐line therapy. The objective response rate (ORR) was 60.1% (57.0% for first‐line recipients, 61.8% for second−/later‐line). Median (95% CI) progression‐free survival (PFS) was 13.7 (11.6–17.0) months. For first‐line recipients, overall survival (OS) was 26.3 (17.6–35.0) months. No significant difference in ORR, PFS and OS, according to the setting of crizotinib initiation, was observed. In a multivariate Cox regression analysis, old age, male gender, initially metastatic, and number of metastatic organs were associated with poor PFS and OS. The most common adverse events were nausea and vomiting, and severe adverse event leading to dose adjustment was hepatotoxicity. Conclusions ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials. Our findings could aid in the efficient management of ALK‐positive lung cancer patients. |
| first_indexed | 2024-03-07T22:56:03Z |
| format | Article |
| id | doaj.art-2f6fe30c7c754b55b863f231b24d86f8 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-03-07T22:56:03Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-2f6fe30c7c754b55b863f231b24d86f82024-02-23T02:10:40ZengWileyThoracic Cancer1759-77061759-77142024-02-0115644845710.1111/1759-7714.15213Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South KoreaDa Som Jeon0Cheol‐kyu Park1Seung Joon Kim2Chan Kwon Park3Yoon Soo Chang4Chi Young Jung5Sung Yong Lee6Shin‐Yup Lee7Jeong‐Seon Ryu8Jeong Eun Lee9Kye Young Lee10Tae Won Jang11Seung Hun Jang12Seong Hoon Yoon13Sang Hoon Lee14Chang‐min Choi15Hyeong Ryul Kim16Yeon Joo Kim17Department of Pulmonary and Critical Care Medicine Nowon Eulji Medical Center, University of Eulji Seoul South KoreaDepartment of Pulmonary and Critical Care Medicine Chonnam National University Hwasun hospital, Chonnam National University Jeollanam‐do Republic of KoreaDepartment of Internal Medicine Postech‐Catholic Biomedical Engineering Institute, College of Medicine, The Catholic University of Korea Seoul Republic of KoreaDepartment of Pulmonary and Critical Care Medicine Catholic University of Korean Yeouido Saint Mary's Hospital Seoul KoreaDepartment of Internal Medicine Yonsei University College of Medicine, 8th Floor Annex Building, Yongdong Severance Hospital Seoul Republic of KoreaDepartment of Internal Medicine Daegu Catholic University School of Medicine Daegu KoreaDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine Seoul KoreaDivision of Pulmonary and Critical Care Medicine Kyungpook National University Chilgok Hospital Daegu KoreaDepartment of Pulmonary and Critical Care Medicine Inha University Hospital Incheon Republic of KoreaDepartment of Internal Medicine Chungnam National University Hospital Daejeon Republic of KoreaDepartment of Pulmonary Medicine Konkuk University School of Medicine Seoul Republic of KoreaDepartment of Internal Medicine Kosin University Medical College Pusan KoreaDepartment of Pulmonary Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital Anyang Republic of KoreaDepartment of Internal Medicine School of Medicine, Pusan National University Yangsan Republic of KoreaDivision of Pulmonology, Institute of Chest Disease, Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of KoreaDepartment of Pulmonary and Critical Care Medicine Asan Medical Centre, University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Pulmonary and Critical Care Medicine Asan Medical Centre, University of Ulsan College of Medicine Seoul Republic of KoreaDepartment of Pulmonary and Critical Care Medicine Nowon Eulji Medical Center, University of Eulji Seoul South KoreaAbstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been approved as a treatment for ALK‐positive NSCLC. This study aimed to analyze the real‐world efficacy and outcome when administered crizotinib, the first approved target agent for ALK‐positive NSCLC, according to first‐ or late‐line treatment. Methods A total of 290 patients with ALK‐positive advanced NSCLC who were treated with crizotinib in 15 institutions in South Korea from January 2009 to December 2018 were enrolled. Results The median age of patients was 57.0 years, and 50.3% were male. The median follow‐up duration was 29.3 months. Among them, 113 patients received crizotinib as first‐line therapy. The objective response rate (ORR) was 60.1% (57.0% for first‐line recipients, 61.8% for second−/later‐line). Median (95% CI) progression‐free survival (PFS) was 13.7 (11.6–17.0) months. For first‐line recipients, overall survival (OS) was 26.3 (17.6–35.0) months. No significant difference in ORR, PFS and OS, according to the setting of crizotinib initiation, was observed. In a multivariate Cox regression analysis, old age, male gender, initially metastatic, and number of metastatic organs were associated with poor PFS and OS. The most common adverse events were nausea and vomiting, and severe adverse event leading to dose adjustment was hepatotoxicity. Conclusions ORR, PFS, OS, and adverse event profiles were comparable to previous clinical trials. Our findings could aid in the efficient management of ALK‐positive lung cancer patients.https://doi.org/10.1111/1759-7714.15213adverse eventsanaplastic lymphoma kinasecrizotinibnon‐small cell lung carcinomaprogression‐free survival |
| spellingShingle | Da Som Jeon Cheol‐kyu Park Seung Joon Kim Chan Kwon Park Yoon Soo Chang Chi Young Jung Sung Yong Lee Shin‐Yup Lee Jeong‐Seon Ryu Jeong Eun Lee Kye Young Lee Tae Won Jang Seung Hun Jang Seong Hoon Yoon Sang Hoon Lee Chang‐min Choi Hyeong Ryul Kim Yeon Joo Kim Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea Thoracic Cancer adverse events anaplastic lymphoma kinase crizotinib non‐small cell lung carcinoma progression‐free survival |
| title | Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea |
| title_full | Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea |
| title_fullStr | Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea |
| title_full_unstemmed | Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea |
| title_short | Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea |
| title_sort | real world outcome of crizotinib for anaplastic lymphoma kinase positive lung cancer multicenter retrospective analysis in south korea |
| topic | adverse events anaplastic lymphoma kinase crizotinib non‐small cell lung carcinoma progression‐free survival |
| url | https://doi.org/10.1111/1759-7714.15213 |
| work_keys_str_mv | AT dasomjeon realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT cheolkyupark realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT seungjoonkim realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT chankwonpark realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT yoonsoochang realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT chiyoungjung realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT sungyonglee realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT shinyuplee realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT jeongseonryu realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT jeongeunlee realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT kyeyounglee realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT taewonjang realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT seunghunjang realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT seonghoonyoon realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT sanghoonlee realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT changminchoi realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT hyeongryulkim realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea AT yeonjookim realworldoutcomeofcrizotinibforanaplasticlymphomakinasepositivelungcancermulticenterretrospectiveanalysisinsouthkorea |